









市場行情
/
股票
/
nasdaq-dnli
/

Denali Therapeutics Inc

DNLI

16.510USD

+0.100+0.61%

收盤 12/31, 16:00（美東）報價延遲15分鐘

2.42B總市值

虧損本益比TTM



Denali Therapeutics Inc

16.510

+0.100+0.61%

概覽公司財務分析

概覽

公司

財務

分析

關於 Denali Therapeutics Inc 公司

Denali Therapeutics Inc. is a biopharmaceutical company. The Company is focused on developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for the treatment of neurodegenerative diseases and lysosomal storage diseases. It has developed a technology, called the TransportVehicle (TV), to address the BBB challenge. Its advanced TV-enabled program is tividenofusp alfa (DNL310, ETV:IDS) for the potential treatment of mucopolysaccharidosis II (MPS II or Hunter syndrome). Its TV-enabled clinical development portfolio also includes DNL126 (ETV:SGSH) for MPS IIIA (Sanfilippo syndrome) and DNL593 (PTV:PGRN) for frontotemporal dementia-granulin (FTD-GRN). Its small-molecule clinical development portfolio includes BIIB122/DNL151 (small molecule LRRK2 inhibitor) for Parkinson’s disease; and DNL343 (small molecule eIF2B activator) for amyotrophic lateral sclerosis (ALS). It is also exploring programs in oncology, inflammation, and other diseases.

Denali Therapeutics Inc簡介



公司代碼DNLI

公司名稱Denali Therapeutics Inc

上市日期Dec 08, 2017

CEOWatts (Ryan J)

員工數量422

證券類型Ordinary Share

年結日Dec 08

公司地址161 Oyster Point Blvd.

城市SOUTH SAN FRANCISCO

上市交易所NASDAQ OMX - NASDAQ BASIC

國家United States of America

郵編94080

電話16508668547

網址https://www.denalitherapeutics.com

公司代碼DNLI

上市日期Dec 08, 2017

CEOWatts (Ryan J)

Denali Therapeutics Inc公司高管



名稱

名稱/職務

職務

持股

持股變動

Dr. Ryan J. Watts, Ph.D.

President, Chief Executive Officer, Director

2.46M

Dr. Alexander O. Schuth, M.D.

Chief Operating and Financial Officer, Secretary

765.12K

-0.38%

Mr. Jay T. Flatley

Independent Director

352.53K

+1.74%

Dr. David P. Schenkein, M.D.

Independent Director

72.72K

+9.05%

Mr. Peter S. Klein

Independent Director

27.53K

+28.08%

Ms. Jennifer E. Cook

Independent Director

26.07K

+30.13%

Dr. Marc Tessier-Lavignec, Ph.D.

Independent Director

Mr. Steven E. (Steve) Krognes

Director

Ms. Nancy A. Thornberry

Independent Director

Mr. Julian C. Baker

Independent Chairman of the Board

名稱

名稱/職務

職務

持股

持股變動

Dr. Ryan J. Watts, Ph.D.

President, Chief Executive Officer, Director

2.46M

Dr. Alexander O. Schuth, M.D.

Chief Operating and Financial Officer, Secretary

765.12K

-0.38%

Mr. Jay T. Flatley

Independent Director

352.53K

+1.74%

Dr. David P. Schenkein, M.D.

Independent Director

72.72K

+9.05%

Mr. Peter S. Klein

Independent Director

27.53K

+28.08%

Ms. Jennifer E. Cook

Independent Director

26.07K

+30.13%

收入明細

由於公司未披露，未能獲取相關數據

由於公司未披露，未能獲取相關數據

業務

地區

由於公司未披露，未能獲取相關數據

股東統計

更新時間: 11月30日週日

持股股東

股東類型

持股股東

佔比

The Vanguard Group, Inc.

7.68%

Baillie Gifford & Co.

7.44%

BlackRock Institutional Trust Company, N.A.

6.50%

Biogen Inc

4.59%

T. Rowe Price Investment Management, Inc.

3.62%

其他

70.17%

持股股東

佔比

The Vanguard Group, Inc.

7.68%

Baillie Gifford & Co.

7.44%

BlackRock Institutional Trust Company, N.A.

6.50%

Biogen Inc

4.59%

T. Rowe Price Investment Management, Inc.

3.62%

其他

70.17%

股東類型

持股股東

佔比

Investment Advisor

50.30%

Investment Advisor/Hedge Fund

18.27%

Hedge Fund

13.58%

Sovereign Wealth Fund

5.97%

Individual Investor

4.64%

Corporation

4.59%

Research Firm

2.24%

Bank and Trust

1.01%

Private Equity

0.64%

機構持股



更新時間: 12月8日週一

報告期間

機構數

持股數

持股佔比

持股變動

2025Q4

523

144.23M

92.59%

-5.13M

2025Q3

534

148.30M

106.07%

+2.76M

2025Q2

533

144.90M

104.92%

+4.11M

2025Q1

521

140.91M

100.82%

-5.51M

2024Q4

508

135.26M

104.03%

-2.70M

2024Q3

500

139.34M

103.43%

+2.39M

2024Q2

486

129.82M

93.98%

+2.48M

2024Q1

475

127.09M

84.98%

+6.07M

2023Q4

485

116.85M

84.85%

+2.16M

2023Q3

479

114.98M

85.46%

+1.16M

股東持股明細



名稱

持股數

佔比

持股變動

變動比例

公告日期

The Vanguard Group, Inc.

11.96M

7.68%

+173.41K

+1.47%

Sep 30, 2025

Baillie Gifford & Co.

11.59M

7.44%

-363.74K

-3.04%

Sep 30, 2025

BlackRock Institutional Trust Company, N.A.

10.13M

6.5%

+257.90K

+2.61%

Sep 30, 2025

Biogen Inc

7.16M

4.59%

-5.60M

-43.89%

Oct 30, 2024

T. Rowe Price Investment Management, Inc.

5.64M

3.62%

+2.39M

+73.66%

Sep 30, 2025

State Street Investment Management (US)

5.46M

3.51%

+946.27K

+20.94%

Sep 30, 2025

Temasek Holdings Pte. Ltd.

5.36M

3.44%

Sep 30, 2025

Fidelity Management & Research Company LLC

5.01M

3.22%

-2.40M

-32.37%

Sep 30, 2025

Capital Research Global Investors

4.76M

3.06%

+10.28K

+0.22%

Sep 30, 2025

T. Rowe Price Associates, Inc.

4.43M

2.85%

-2.03M

-31.37%

Sep 30, 2025

持股ETF



更新時間: 12月6日週六

機構名稱

佔比

iShares Neuroscience and Healthcare ETF

4.13%

Global X Guru Index ETF

1.33%

ALPS Medical Breakthroughs ETF

0.98%

Virtus LifeSci Biotech Clinical Trials ETF

0.74%

State Street SPDR S&P Biotech ETF

0.73%

Direxion Daily S&P Biotech Bull 3X Shares

0.45%

Global X Aging Population ETF

0.38%

ProShares Ultra Nasdaq Biotechnology

0.35%

iShares Health Innovation Active ETF

0.35%

Invesco Nasdaq Biotechnology ETF

0.23%

iShares Neuroscience and Healthcare ETF

佔比4.13%

Global X Guru Index ETF

佔比1.33%

ALPS Medical Breakthroughs ETF

佔比0.98%

Virtus LifeSci Biotech Clinical Trials ETF

佔比0.74%

State Street SPDR S&P Biotech ETF

佔比0.73%

Direxion Daily S&P Biotech Bull 3X Shares

佔比0.45%

Global X Aging Population ETF

佔比0.38%

ProShares Ultra Nasdaq Biotechnology

佔比0.35%

iShares Health Innovation Active ETF

佔比0.35%

Invesco Nasdaq Biotechnology ETF

佔比0.23%

分紅派息



近5年累計派現 0.00 美元

公告日期

分紅計劃

股權登記日

現金發放日

除權除息日

暫無數據

拆合股



公告日期

類型

比率

暫無數據

公告日期

類型

比率

暫無數據

常見問題

Denali Therapeutics Inc的前五大股東是誰？



Denali Therapeutics Inc的前五大股東如下：
The Vanguard Group, Inc.
持有股份：11.96M
佔總股份比例：7.68%。
Baillie Gifford & Co.
持有股份：11.59M
佔總股份比例：7.44%。
BlackRock Institutional Trust Company, N.A.
持有股份：10.13M
佔總股份比例：6.50%。
Biogen Inc
持有股份：7.16M
佔總股份比例：4.59%。
T. Rowe Price Investment Management, Inc.
持有股份：5.64M
佔總股份比例：3.62%。